<DOC>
	<DOCNO>NCT01943461</DOCNO>
	<brief_summary>This Phase 1 , open-label , dose-escalation trial avelumab ( antibody target program death ligand 1 [ anti PD-L1 ] ) Japanese subject metastatic locally advanced solid tumor , follow consecutive expansion part Asian subject gastric cancer .</brief_summary>
	<brief_title>Avelumab Metastatic Locally Advanced Solid Tumors ( JAVELIN Solid Tumor JPN )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Signed write informed consent Male female subject age great equal 20 year For dose escalation part : Histologically cytologically proven metastatic locally advanced solid tumor , standard therapy exist standard therapy fail For expansion part : Availability fresh archive tumor formalin fix paraffin embed tissue With histologically cytologically confirm recurrent refractory unresectable Stage IV gastric gastroesophageal junctional adenocarcinoma ( accord American Joint Committee Cancer/Union Internationale Contre le Cancer [ UICC ] 7th edition ) whose disease progress one two prior chemotherapy regimen ( ) involve fluoropyrimidines platinum Presence least 1 measurable lesion accord RECIST version 1.1 Subjects severe peritoneal metastasis . The following criterion apply : No clinical ileus subileus No moderatetosevere ascites ( subject ascites restricted perihepatic space pelvic cavity ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 trial entry estimate life expectancy least 3 month Adequate hematological , hepatic renal function define protocol All subject must agree use effective mean contraception partner entry trial 6 month last dose avelumab Concurrent treatment nonpermitted drug Prior therapy antibody/drug target T cell coregulatory protein ( immune checkpoint ) Concurrent anticancer treatment concurrent systemic therapy steroid immunosuppressive agent , use investigational drug within 30 day start trial treatment . Shortterm administration steroid ( , allergic reaction management immunerelated adverse event [ irAE ] ) allow Previous malignant disease within last 5 year exception adequately treat nonmelanoma skin cancer , situ cancer , cancer Nononcology vaccine therapy prevention infection disease ( e.g . seasonal flu vaccine , human papilloma virus vaccine ) within 4 week study drug administration . Vaccination study also prohibit except administration inactivate influenza vaccine . Pregnancy lactation period Known alcohol drug abuse Clinically significant ( , active ) cardiovascular disease All significant disease ( example , inflammatory bowel disease ) , , opinion investigator , might impair subject 's tolerance trial treatment Any psychiatric condition would prohibit understanding rendering informed consent Legal incapacity limit legal capacity Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>MSB0010718C</keyword>
	<keyword>anti PD-L1</keyword>
	<keyword>avelumab</keyword>
	<keyword>Phase 1</keyword>
</DOC>